New Product:FDA Approves Aliskiren/HCTZ Antihypertensive Pill for First-Line Use

The US Food and Drug Administration has approved a new indication for a single-tablet combination of the renin inhibitor aliskiren (Tekturna® HCT) and the diuretic hydrochlorothiazide for the first-line treatment of hypertension in patients likely to require multiple medications to achieve their blood pressure goals. The combination tablet previously was approved for second-line use only.